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Crouzon syndrome is a dominantly inherited disorder charac-
terized by craniosynostosis and facial dysostosis, caused by
mutations in the ﬁbroblast growth factor receptor 2 (FGFR2)
gene;itbelongstoaclassofdisordersthatmostlyariseasdenovo
mutations and exhibit a near-exclusive paternal origin of muta-
tion and elevated paternal age (‘‘paternal age effect’’). However,
even if this is the major mode of origin of mutations in paternal
age-effect disorders, germline mosaicism may also occur. Here
we describe the ﬁrst molecularly documented evidence of germ-
line and somatic mosaicism for FGFR2 mutation, identiﬁed in
the mother of a child with Crouzon syndrome caused by a
heterozygous c.1007A>G (p.Asp336Gly) substitution. Levels of
maternal somatic mosaicism for this mutation, estimated by
pyrosequencing, ranged from 3.3% in hair roots to 14.1% in
blood. Our observation underlines the importance of parental
molecular testing for accurate genetic counseling of the risk
of recurrence for Crouzon, and other paternal age-effect
syndromes.   2010 Wiley-Liss, Inc.
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INTRODUCTION
Crouzonsyndrome(OMIM#123500)comprisescraniosynostosis,
exorbitism, hypertelorism, midface hypoplasia, hooked nose,
thin vermilion of the upper lip and mandibular prognathism,
leadingtodentalmalocclusion.Althoughthelimbsaretraditionally
described as normal, subtle alterations, for example in metacarpo-
phalangeal proportions of the hands, are a consistent ﬁnding
[Murdoch-Kinch and Ward, 1997]. Crouzon syndrome is caused
by over 40 different heterozygous missense mutations in the
ﬁbroblast growth factor receptor 2 (FGFR2) gene [reviewed in
Passos-Bueno et al., 2008]. Although Crouzon syndrome is inher-
ited as an autosomal dominant trait, many cases are sporadic and
presentasdenovomutationsarisingfromunaffectedparents.Such
de novo mutations were found to arise exclusively on the father’s
allele(n¼11)andtoexhibitapaternalageeffect(increasedaverage
age of the father compared to the population mean) [Glaser et al.,
2000]. Similar observations have been made for other disorders
involving dominant mutations in FGFR2 or FGFR3-including
Apert [Moloney et al., 1996], Pfeiffer [Glaser et al., 2000], and
Muenke[Rannan-Eliyaetal.,2004]syndromesandachondroplasia
[Wilkin et al., 1998].
There is now good evidence that this class of so-called ‘‘paternal
age-effect’’ mutations originate as rare spontaneous events within
spermatogonial cells of adult males. Because they confer a selective
advantage to the mutant stem or progenitor cells, these mutations
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sion, resulting in elevated levels of mutation in sperm [Goriely
et al., 2009]. Although it is well documented that the relative risk
increases with advancing paternal age, there is nevertheless a very
low absolute probability of recurrence within a family, usually
estimated to be well under 1% [Mettler and Fraser, 2000].
Apparently at variance with this usual mechanism of mutation
in paternal age-effect syndromes, several instances of germline
mosaicism in Crouzon syndrome have been suggested [Rollnick,
1988; Kreiborg and Cohen,1990; Navarrete et al., 1991].However,
all these reports predated the identiﬁcation of FGFR2 mutations
in Crouzon syndrome [Reardon et al., 1994] and none has been
molecularly conﬁrmed. Here, we present the ﬁrst molecularly
proven case of germline and somatic mosaicism for FGFR2 muta-
tion and discuss the implication of this ﬁnding in the context of
recurrence risk estimation for paternal age-effect disorders as a
whole.
MATERIALS AND METHODS
Identiﬁcation of FGFR2 Mutation
The study was approved by the Oxfordshire Research Ethics
Committee B (C02.143) and written informed consent was
obtained from the parents. Genomic DNA was extracted from
saliva using the OrageneDNA OG-250 kit (DNA Genotek, Kanata,
Ontario, Canada) following the manufacturer’s instructions, and
from peripheral blood and/or hair roots by proteinase K digestion
and phenol/chloroform extraction. Nomenclature for FGFR2 (IIIc
spliceform) follows the cDNA reference sequence (Genbank
NM_000141.4,wherethenumberingofthecDNAnucleotidestarts
withþ1attheAoftheATGinitiationcodon).PCRandsequencing
of FGFR2 exons containing hotspots of mutations for craniosyn-
ostosis syndromes (exons 8 [IIIa] and 10 [IIIc]; nomenclature
according to Kan et al. [2002]) was initially performed in a clinical
diagnostic laboratory; mutations in exon IIIa were excluded. For
further sequence analysis, ampliﬁcation of exon 10 (IIIc) was
performed in a 30mlPCRreaction using ExpandHigh Fidelity
PLUS
PCR system reagents (Roche Applied Biosystems, Mannheim,
Germany) in thefollowingconditions: 1 Hiﬁ
PLUSbuffer, 2.5mM
MgCl2, 0.75 U Hiﬁ
PLUS DNA polymerase, 200mM dNTPs and
0.1mM each primer (50-CCTCCACAATCATTCCTGTGTC-30
and 50-ATAGCAGTCAACCAAGAAAAGGG-30). The following
cycling conditions were used: initial 94 C for 2min, followed by
30cyclesof94 Cfor10sec,62 Cfor30sec,72 Cfor30sec,followed
by a ﬁnal extension at 72 C for 10min. After checking for ampliﬁ-
cation on a 2% agarose gel, the fragments were gel-puriﬁed using
a gel extraction microelute column (EZNA, Omega Bio-Tek,
Norcross, GA). The amplicons were then subjected to sequencing
in both orientations using the PCR primers and ﬂuorescently
labeled dideoxy-terminator reactions and run on an ABI 3700
automated DNA sequencer (Applied Biosystems, Carlsbad, CA).
Restriction digest with HgaI (New England Biolabs, Ipswich,
CA) was performed on 15ml of the pyrosequencing PCR product
(see below) in a 30ml reaction containing 1  Buffer 1 and 5U of
HgaI for 4hr at 37 C. The resulting digest was run on a 4% TBE
agarose gel.
Microsatellite analysis (D10S1483) was performed after ampli-
ﬁcation with the primers 50-FAM-CAATGCTATCCCGGCTATG-
30 and 50-TCAAGACTGCAAGCGTGT-30 in Invitrogen (Carlsbad,
CA) PCRreagents(1  PCRbuffer,2.5mM MgCl2,1UTAQ DNA
polymerase, 200mM dNTPs, 0.1mM each primer and 20–50ng
genomic DNA) with the cycling conditions: initial 94 C for 2min,
followed by 35 cycles of 94 C for 15sec, 56 C for 30sec, and 72 C
for30sec. TheDNA fragmentanalysis wasperformed onABI3730
DNA Analyzer and scored using the GeneMapper software
(Applied Biosystems).
Pyrosequencing
The following pyrosequencing primers were designed to amplify a
132bp FGFR2 exon IIIc fragment: 50-TAACACCACGGACAAAG
AGATTGAGGTTCTC-30 and 50-Biotin-GGCAGAACTGTCAAC
CATGCAGAGTGAA-30 using High Fidelity PCR system reagents
(RocheAppliedBiosystems)ina60mlPCRreactioncontaining1 
Hiﬁ buffer, 1.5mM MgCl2, 0.5U Hiﬁ DNA polymerase, 200mM
dNTPs, 0.1mM each primer and 20–50ng genomic DNA with the
cycling conditions: initial 94 C for 2min, followed by 35 cycles of
94 C for 10sec, 62 C for 30sec, 68 C for 30sec, followed by a ﬁnal
extension at 68 C for 10min. This PCR reaction was performed
threetimesindependentlyandaftercheckingforampliﬁcationona
2%agarosegel,10mlofeachPCRproductwaspyrosequencedtwice
on a PyroMark Q96 MD (Qiagen, Hilden, Germany) using the
sequencingprimer50-CGGAATGTAACTTTTG-30 andfollowinga
protocol previously described [Twigg et al., 2006]. After dispensa-
tion of the enzyme (E) and substrate (S), the nucleotides were
dispensed in the order A-C-G-C-G-T-C-A-G-C-G-T-C-T. This
order generates four peaks speciﬁc for the normal c.1007A allele
(dispensations C10,G 11,C 13, and T14) and four mutant-speciﬁc
peaks (C4,G 5,C 7, and T12), which were averaged to estimate the
relativelevelsofc.1007Gmutantallele.Analysisofthepeakheights
follows the same principles described in Twigg et al. [2006].
RESULTS
The proposita II-1, the ﬁrst of two children born to healthy,
nonconsanguineous north-European parents (Fig. 1A), presented
attheageof12yearswithrecurrentotitismedia,conductivehearing
lossandvisualdisturbance.Grommets(tympanostomytubes) had
been inserted at age 5 years and spectacles prescribed at 12 years.
Exorbitism was noted at the time of the ophthalmological exami-
nation and she was referred for a clinical genetics opinion at
whichtimeitwasnoticedthatshehadmidfacehypoplasia,ocular
proptosis, hypertelorism, frontal bossing, short upper lip, mild
prognathism (Fig. 2A), a high narrow palate, dental crowding,
mild2/3cutaneoussyndactylyofherhands(Fig.2B)andbilateral
syndactyly of the second and third toes (Fig. 2C). No intellectual
or developmental impairment was apparent and there was
no signiﬁcant family history. 3D-computed tomography of the
skull showed pan-synostosis and absence of sutures as well as
reduced space with copper beating suggestive of raised intra-
cranialpressure(ICP).However,directmeasurementofICPwas
normal,andsheisbeingmanagedconservativelypendingadetailed
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overlap zone between Pfeiffer and Crouzon syndromes, which are
also known to overlap at the molecular level [Rutland et al., 1995;
Kan et al., 2002]; Crouzon syndrome was favored as the ﬁnal
diagnosisbecauseofthelatepresentationandthemildcraniofacial
phenotype.
Analysis of mutation hotspots in FGFR2 (exons IIIa and IIIc)
performed on blood genomic DNA showed a heterozygous
c.1007A>Gmutation,encodingap.Asp336Glysubstitutionwithin
the third immunoglobulin-like domain of FGFR2 (Fig. 1B). This
mutation has been reported once previously, also in a patient
diagnosed with Crouzon syndrome [Stenirri et al., 2007].
Subsequently, genetic testing of peripheral blood from the
patient’s parents was requested. The father’s FGFR2 sequence was
normal (Fig. 1C), but the sample from the mother (I-2), 28.5 years
at the time of the girl’s birth, was found to be mosaic for the same
c.1007A>G mutation (Fig. 1D). She appeared to be clinically
normal (Fig. 2D–F), and her skin (including examination under
a Wood’s lamp) was normal. Further maternal samples, including
hair roots and saliva were obtained and tested. Direct sequencing
showed that the mutation could be detected at variable levels in all
tissues(Fig.1E,F).Thisresultwasfurtherveriﬁedusingadiagnostic
restrictiondigest(Fig.1G).TheFGFR2mutationwasnotpresentin
a mouth-brushing sample from the patient’s clinically normal
FIG. 1. FGFR2exonIIIcsequenceandrestrictionenzymedigestionA:PedigreeindicatingthesegregationofthemicrosatelliteD10S1483located6.7kb
awayfromthesiteoftheFGFR2mutationintheproposita(II-1),showingthatthetwosibshaveinheritedoppositematernalFGFR2alleles.B–F:DNA
sequencing chromatograms around the mutation site (p.Asp336 codon corresponding to the GACboxed sequence) in FGFR2 exon IIIc (B,C:reverse
complementary sequence of the minus strand; D–F: forward sequence of the plus strand); the proposita’s blood DNA (B) shows a heterozygous
c.1007A>G mutationencoding a p.Asp336Glysubstitution; (C)the same changeis absent fromthe father’s blood DNA. D–F:Chromatograms from
the mother’s blood (D), saliva (E) and hair roots (F) genomic DNA, revealing a variable amount of the c.1007A>G mutation in these tissues
(arrowheads).G:HgaIrestrictiondigestofa132bpPCRproductforthedifferentgenomicDNAsamples(asindicated),showsthatthenormalallele
(c.1007A),iscutintotwofragments(65and67bp),whilethec.1007A>GmutationabolishestheHgaIrestrictionsite(GACGCN5).Comparisonofthe
ratio of mutant (upper undigested fragment) to normal (lower fragments) alleles in the maternal samples to that of the heterozygous proposita,
shows that the relative amount of undigested fragment is reduced in the mother’s blood and saliva samples and is barely visible in the hair root
sample(rightandleftlanesare100bpladders).[Colorﬁgurecanbeviewedintheonlineissue,whichisavailableatwww.interscience.wiley.com.]
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ofapolymorphic(CA)nmicrosatellite(D10S1483)located6.7kb50
of the FGFR2 mutation site, he inherited the opposite maternal
chromosome to his affected sister (Fig. 1A).
Pyrosequencing was used to estimate the levels of mosaicism
morepreciselyinthethreedifferentmaternaltissues.Theassaywas
designedtocomparefourpeaksgeneratedspeciﬁcallytothenormal
allele with four mutant-speciﬁc peaks (Fig. 3A). The assay was
validated by measuring the levels of mutant allele in the heterozy-
gous proposita DNA, where the FGFR2 c.1007A>G mutation was
estimated to be at a level of 48.9% ( 0.4%) (Fig. 3B), and in the
normal control paternal DNA, where it was found to be at a
background level of 1.2% ( 0.4%) (Fig. 3C). After adjustment of
the raw measurements by linear interpolation, we conﬁrmed the
mosaicisminthematernalsamplesandestimatedtheproportionof
the c.1007G allele to be 14.1% ( 0.6%) in blood (Fig. 3D), 13.3%
( 0.4%) in saliva (Fig. 3E) and 3.3% ( 1.1%) in hair roots
(Fig. 3F).
DISCUSSION
We report on the ﬁrst molecularly proven case of a somatic and
germline mosaicism for a dominant mutation in the FGFR2 gene.
The heterozygous c.1007A>G (p.Asp336Gly) substitution appears
to cause a fairly mild phenotype, as the proposita was diagnosed
with Crouzon syndrome only at the age of 12 years and has not yet
required surgery. A similar presentation of postnatal craniosynos-
tosis and increased ICP in Crouzon syndrome was described
previously [Connolly et al., 2004; Hoefkens et al., 2004] and
although ICP measurements were normal in the proposita, she
FIG. 2. Phenotypeofthepropositaandhermother.A–C:Proposita(II-1),age12years.A:Facialappearanceofthepatientatthetimeofdiagnosis.Note
hypertelorism, exorbitism, midface hypoplasia, frontal bossing, and mild prognathism. B: Hands of the proposita showing mild 2/3 cutaneous
syndactyly and normal thumbs. C: Proposita’s feet showing normal big toes and bilateral syndactyly of second and third toes. D,E: Mother of the
proposita(I-2),age40years.D:Herfaceisnormalandshedoesnotdisplayanycrouzonoidfeatures.E,F:Herhandsandfeetappearnormal.[Color
ﬁgure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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changes suggestive of increased ICP.
Crouzon syndrome belongs to a group of genetic disorders that
have been termed ‘‘paternal age-effect’’ disorders to reﬂect the fact
thatthedominantlyactingcausativemutations, whentheyarisede
novo, exhibit a near-exclusive paternal origin and an increased
paternalage[Crow,2000;reviewedinGorielyetal.,2009].Aswellas
mutations in FGFR2 and FGFR3, mutations in RET (causing
multiple endocrine neoplasia types 2A and 2B), PTPN11
(causing Noonan syndrome) and HRAS (causing Costello
syndrome) also belong to this group [reviewed in Goriely et al.,
2009]. Recently, it was proposed that the causative mutations
responsible for the paternal age-effect disorders originate by a
shared mechanism taking place during spermatogenesis. These
mutations arise as rare events in the testes of most or all men,
duringtherepeatedmitoticreplicationsofthespermatogonialstem
or progenitor cells required for the production of mature sperm.
Because they encode dominant gain-of-function proteins, the
paternal age-effect mutations confer a selective advantage to the
spermatogonial cells in which they originate, leading to clonal
FIG. 3. PyrosequencingandquantiﬁcationofthemosaicismlevelsfortheFGFR2c.1007A>Gmutation.A:Pyrosequencingschemeshowingatablewith
the sequencecontext ofthe 2FGFR2alleles (normal c.1007A (above) andmutantc.1007G(below)) andthe sequencing primer (Pyroseq primer).
The allele-speciﬁc incorporation of nucleotides is listed for each dispensation (denoted by the numbers on the right side in each box). Below, the
dispensation order in which the nucleotides are added is indicated. This generates four mutant-speciﬁc peaks (at the 4th, 5th, 7th, and 12th
dispensations)andfourpeaksuniqueforthenormalallele(the10th,11th,13th,and14thdispensations).B–F:Typicalpyrogramsshowingthefour
mutant-speciﬁcpeaks(redarrows)andthenormalallele-speciﬁcpeaks(bluearrowheads)fortheproposita’sbloodDNA(B),thefather’sbloodDNA
(C), the mother’s blood DNA (D), mother’s saliva DNA (E) and mother’s hair root DNA (F). [Color ﬁgure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
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et al., 2003, 2005, 2009]. Although the resulting enrichment of
sperm carrying a paternal age-effect mutation could formally be
considered ‘‘germline mosaicism,’’ direct measurements of muta-
tion levels in sperm have shown that thesedo not exceed 1 in 1,000
[Gorielyetal.,2003,2005,2009;Choietal.,2008;Yoonetal.,2009].
For this reason, a healthy couple with a single child with one of the
paternalage-effectdisorderswillgenerallybecounseledashavinga
low recurrence risk (below 1%). However, it is important to
distinguish this from the classical process of germline mosaicism,
which can occur in both males and females, originates in the early
embryo rather than in the adult and as a result, carries a risk of
recurrence in offspring that is several orders of magnitude higher
(up to 1 in 2).
As exempliﬁed in this report, even if most new cases of pater-
nalage-effectsyndromesariseasdenovomutationsinthepaternal
germline, they can also occur by a classical mechanism of parental
mosaicism. Whilst this is an unusual situation, it is not unique to
FGFR2 and similar cases have been documented for FGFR3 muta-
tions in achondroplasia [Henderson et al., 2000; Natacci et al.,
2008]andinthanatophoricdysplasia[Hylandetal.,2003],andfor
HRAS mutations in Costello syndrome [Gripp et al., 2006; Sol-
Churchetal.,2009].Generallythesecasescametoattentionafterit
wasnoticedeitherthat(1)morethanonepregnancywasaffectedin
a sibship or (2) one of the parents showed partial manifestation of
the disorder. In the present report, despite the fact that neither of
these criteria was present, the sequence analysis of the DNA of the
patient’s parents showed that the mother, who is phenotypically
normal, is mosaic for the FGFR2 c.1007A>G mutation carried by
her affected daughter. As this is a heterozygous mutation, we
estimated that 25–30% of her blood and saliva cells and less than
10%ofherhairrootcellscarrythemutation.Sinceherdaughterhas
inherited the FGFR2 c.1007A>G substitution as a germline muta-
tion,itmustbepresentinthemother’sgermcellsaswell.Therefore,
the mother presents with somatic and germline mosaicism. As we
establishedthatherunaffectedsoninheritedtheoppositematernal
alleletohissister’s,itremainspossiblethatalargeproportionofthe
mother’s germ cells carry the pathogenic c.1007A>G mutation,
leading to an offspring recurrence risk up to 50%. Although
FGFR2somaticmosaicism—causingacneiformnaevusintheepid-
ermis—hasbeendocumentedpreviously[MunroandWilkie,1998;
Melniketal.,2008],toourknowledge,thepresentreportistheﬁrst
case of molecularly proven germline and somatic mosaicism for a
FGFR2 mutation.
Inconclusion,thisreportunderlinestheimportanceofchecking
for parental mosaicism even in apparently de novo paternal age
effect syndromes. With current DNA sequencing technology,
detection of somatic mosaicism at levels as low as 10% should
beroutinelypossibleandcounselingofrecurrenceriskforpaternal
age-effect syndromes for a family with a single affected child
improved.
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